Chongqing Cell Bioengineering Technology Co., Ltd.

Chongqing Cell Bioengineering Technology Co., Ltd. (hereinafter referred to as the Company) was jointly invested and established by Zhongyuan Xiehe Cell Gene Engineering Joint-stock Co., Ltd. and the Children's Hospital of Chongqing Medical University. It is a holding subsidiary of an A-share listed company (stock code: 600645), the first listed company in China's A-share market focused on stem cells, and also a stem cell bank integrating stem cell collection, preservation, and provision for clinical application. The Company has strong technical strength and a first-class research team, with 95% of employees holding doctoral, master's, or bachelor's degrees or above. Nearly ten million yuan has been invested to build an international-standard GMP cell production facility with advanced and reliable equipment, and all testing and preservation equipment are of top brands. An advanced stem cell bank database management system is adopted, and an excellent management team with mature business management and stable quality management experience has joined.
The Company is currently located within the Chongqing Children's Hospital, comprising multiple areas including office areas, production bank areas, and cryopreservation bank areas. As a company with more than twenty sub-banks, Zhongyuan Xiehe possesses a complete set of internationally advanced plans and management systems for bank preparation, establishment, operation, and maintenance, which are used to standardize the daily production and maintenance workflows of each branch.
With the purpose of caring for life and serving clinical practice, we actively promote the continuous deepening of stem cell resource preservation and stem cell research, providing more advanced, reliable, and effective biotherapy technologies for scientific research and clinical practice, benefiting the people.